- Home
- Publications
- Publication Search
- Publication Details
Title
Acute myeloid leukaemia
Authors
Keywords
-
Journal
LANCET
Volume 401, Issue 10393, Pages 2073-2086
Publisher
Elsevier BV
Online
2023-04-15
DOI
10.1016/s0140-6736(23)00108-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time to blur the blast boundaries
- (2022) Courtney D. DiNardo et al. CANCER
- Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
- (2022) Nicolas Duployez et al. BLOOD
- The longitudinal dynamics and natural history of clonal haematopoiesis
- (2022) Margarete A. Fabre et al. NATURE
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
- (2022) Pau Montesinos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission
- (2022) Madlen Jentzsch et al. Blood Advances
- Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
- (2022) Andrew H Matthews et al. Blood Advances
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.
- (2022) Stéphane De Botton et al. JOURNAL OF CLINICAL ONCOLOGY
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- (2022) Joseph D. Khoury et al. LEUKEMIA
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML
- (2021) Martin Wermke et al. BLOOD
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- De novo acute myeloid leukemia: A population‐ based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
- (2021) Koji Sasaki et al. CANCER
- Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal
- (2021) Elihu H Estey et al. BLOOD
- Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission
- (2021) Takaaki Konuma et al. BONE MARROW TRANSPLANTATION
- Germline predisposition to hematopoietic malignancies
- (2021) Simone Feurstein et al. HUMAN MOLECULAR GENETICS
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
- (2021) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute promyelocytic leukemia current treatment algorithms
- (2021) Musa Yilmaz et al. Blood Cancer Journal
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
- (2021) Jeffrey E Lancet et al. Lancet Haematology
- Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
- (2021) Sijian Yu et al. JAMA Network Open
- Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
- (2021) Inge van der Werf et al. Blood Advances
- Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
- (2021) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
- (2021) Justin Grenet et al. BLOOD
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
- (2021) Michael Heuser et al. BLOOD
- Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges
- (2021) Kiran Tawana et al. BRITISH JOURNAL OF HAEMATOLOGY
- Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
- (2021) Christopher J. Gibson et al. JOURNAL OF CLINICAL ONCOLOGY
- Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2021) Kelly J. Norsworthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
- (2021) Ing S. Tiong et al. Blood Advances
- Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
- (2021) Keith W. Pratz et al. JOURNAL OF CLINICAL ONCOLOGY
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Molecular MRD status and outcome after transplantation in NPM1-mutated AML
- (2020) Richard Dillon et al. BLOOD
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
- (2020) Christoph Röllig et al. BLOOD
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
- (2020) Claude Gardin et al. Blood Advances
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis
- (2020) Kelly L. Bolton et al. NATURE GENETICS
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- (2020) Amy Burd et al. NATURE MEDICINE
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
- (2020) Nicholas J. Short et al. JAMA Oncology
- Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
- (2020) Charles Craddock et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
- (2020) Nicholas J. Short et al. Blood Advances
- Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
- (2020) Rory M. Shallis et al. BLOOD REVIEWS
- Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
- (2019) Gerwin Huls et al. BLOOD
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
- (2019) Miguel A. Sanz et al. BLOOD
- Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
- (2019) Gunnar Juliusson et al. BLOOD
- Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
- (2019) Rong He et al. MODERN PATHOLOGY
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
- (2019) Megan Othus et al. BONE MARROW TRANSPLANTATION
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal hematopoiesis in human aging and disease
- (2019) Siddhartha Jaiswal et al. SCIENCE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
- (2019) Lukasz P Gondek et al. Lancet Haematology
- Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
- (2018) Chezi Ganzel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays
- (2018) Catherine C. Coombs et al. CLINICAL CANCER RESEARCH
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Managing Clonal Hematopoiesis in Patients With Solid Tumors
- (2018) Kelly L. Bolton et al. JOURNAL OF CLINICAL ONCOLOGY
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)
- (2016) Courtney D. DiNardo et al. Clinical Lymphoma Myeloma & Leukemia
- Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
- (2016) Chezi Ganzel et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
- (2015) R J Molenaar et al. LEUKEMIA
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
- (2014) R B Walter et al. LEUKEMIA
- Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
- (2014) Uri Rozovski et al. LEUKEMIA & LYMPHOMA
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
- (2013) F Ferrara et al. LEUKEMIA
- Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
- (2013) K Takahashi et al. LEUKEMIA
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started